Phaim is dedicated to developing curative treatments for auto-immune diseases. The company is developing a range of novel therapeutic innovations including an exciting new therapy to treat and prevent diabetes and a predictive kit for first-degree relatives. Our long-term goal is the broadening of our platform approach to other autoimmune diseases through our active R & D programme.
We are committed to ensuring that there will be equitable access to all our innovations and products globally. This will be achieved through close association with our sister charitable foundation: DiamEND Foundation www.diamendfoundation.org
Now undergoing preparation for FDA/EMA regulatory approval.